US EditionSkyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
- Skyline Therapeutics is set to unveil a late-breaking abstract on May 13, 2025, at the ASGCT 28th Annual Meeting in New Orleans, showcasing SKG1108, a novel gene therapy utilizing optogenetics to address vision loss in patients with Retinitis Pigmentosa.
- This presentation follows SKG1108's development as a mutation-agnostic AAV gene therapy designed for RP patients with photoreceptor degeneration amid no effective global treatments slowing or reversing this condition.
- In vivo experiments in rd1 mice revealed that a single intravitreal dose of SKG1108 led to notable enhancements in neural visual responses, detection of light stimuli, and behavioral measures of sight, all while maintaining an excellent safety profile and demonstrating strong therapeutic potential.
- In September 2024, SKG1108 was granted Orphan Drug status by the U.S. FDA. The therapy’s research findings were presented as Abstract No. 2023, titled “SKG1108: Optogenetic Gene Therapy Utilizing AAV-BWLP for Vision Recovery in Retinitis Pigmentosa Through a Single Intravitreal Injection.”
- This gene therapy offers a promising new option for most individuals affected by Retinitis Pigmentosa, even those in the later stages of the condition, potentially addressing a significant unmet need in treating genetic causes of vision loss.
37 Articles
37 Articles
The Berkshire Eagle
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025
SHANGHAI, May 10, 2025 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation on SKG1108, its investigational optogenetic gene therapy for…
Skyline Therapeutics Presents Late-Breaking Abstract on SKG1108, a Novel Optogenetic Gene Therapy for Retinitis Pigmentosa, at ASGCT 2025 - PressReach
SHANGHAI, May 10, 2025 /PRNewswire/ — Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract presentation on SKG1108, its investigational optogenetic gene therapy for Retinitis Pigmentosa (RP), at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting (May 13–17, 2025, New Orleans, Lou…
Coverage Details
Bias Distribution
- 79% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
